ClinicalTrials.gg
CompletedNCT03742037Updated Jul 29, 2026Results posted

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

A Phase 2 interventional study of Cenerimod 0.5 mg and Cenerimod 1 mg in Systemic Lupus Erythematosus, sponsored by Viatris Innovation GmbH. Completed at 148 sites in 24 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
427
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
48th of 407
427 · median 70
Started
2018
with 28 others
Phase 2
120 of 477
10 open now
Registered
278th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 48th largest by enrollment of the 407 interventional ones that give a count, is one of 29 that started in 2018, is one of 120 in phase 2, and was the 278th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).

Read the detailed description

This is a Phase 2b, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Musculoskeletal and connective tissue disorders
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Form prior to any study-mandated procedure
  • Diagnosis of SLE made at least 6 months prior to Screening, by fulfilling at least 4 of the 11 criteria for SLE as defined by the American College of Rheumatology (ACR) criteria
  • A mSLEDAI-2K score ≥ 6 of at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
  • Currently treated with stable doses of one or more of the following background medications:

    • NSAIDs
    • Anti-malarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine)
    • Mycophenolate mofetil (≤ 2 g/day)
    • Mycophenolic acid (≤ 1440 mg/day)
    • Azathioprine (≤ 2 mg/kg/day)
    • Methotrexate (≤ 20 mg/week)
    • (≤ 40 mg/day prednisone or equivalent)
    • Belimumab (≤10 mg/kg every 4 weeks intravenously, or 200 mg/week subcutaneously).
  • History or presence of positive autoantibodies measured by central laboratory defined as follows: (a) Positive antinuclear antibody (ANA) test measured by immunofluorescence assay (IFA) with titre ≥1:80; AND/OR (b) positive anti-double stranded deoxyribonucleic acid (anti-dsDNA) antibodies with titre ≥30 IU/mL
  • Women of :

    • Must have a negative serum pregnancy test at Screening
    • Must agree to undertake monthly urine pregnancy tests during the study
    • Must use highly effective methods of from the screening visit until 6 months after taking the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Active lupus nephritis or a renal demonstrating immune complex mediated glomerulonephritis compatible with lupus nephritis.
  • CNS (Central Nervous System) lupus and severe forms of vasculitis requiring systemic treatment
  • A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with rheumatoid arthritis, erosive arthritis, scleroderma or hepatitis
  • History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia or syncope associated with cardiac disorders
  • Subjects who experienced myocardial infarction, unstable angina pectoris, stroke, , vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the Class III/IV within six months prior to Screening
  • An elevated corrected for HR (Heart Rate) on the basis of Fridericia's formula interval of > 470 ms (females) / > 450 ms (males)
  • History or presence of severe respiratory disease or pulmonary fibrosis
  • Active or latent tuberculosis
  • Ongoing bacterial, viral or fungal infection that is of clinical concern in the judgment of the investigator or history of any serious infection
  • Subjects who have congenital or acquired severe immunodeficiency or known infection or positive HIV testing
  • Presence of macular edema or active uveitis
  • Type 1 or 2 diabetes that is poorly controlled according to investigator judgment, or diabetes complicated with organ involvement such as diabetic nephropathy or retinopathy
  • Significant hematology abnormality: Lymphocyte count \< 800 /μL (0.8 × 10e9/L); \< 9 g/dL; WBC (White Blood Cell) count \< 2500/μL (2.5 × 10e9/L) or \< 75000/μL (75 × 10e9/L)
  • Estimated \< 60 mL/min/1.73 m2
  • Known allergy to S1P (sphingosine-1-phosphate) receptor modulators or any of the cenerimod formulation
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
427 participants (actual)

Study arms

  • Experimental
    Cenerimod 0.5 mg

    Participants will receive cenerimod 0.5 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 0.5 mg for a further 6 months and end study treatment at the Month 12 visit.

    Drug: Cenerimod 0.5 mg

  • Experimental
    Cenerimod 1 mg

    Participants will receive cenerimod 1 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 1 mg for a further 6 months and end study treatment at the Month 12 visit.

    Drug: Cenerimod 1 mg

  • Experimental
    Cenerimod 2 mg

    Participants will receive cenerimod 2 mg once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with cenerimod 2 mg for a further 6 months and end study treatment at the Month 12 visit.

    Drug: Cenerimod 2 mg

  • Experimental
    Cenerimod 2 mg (Ex-4mg)

    Half the participants that complete treatment with cenerimod 4 mg in Treatment Period 1 will be re-randomized to cenerimod 2 mg once daily in addition to background SLE therapy during Treatment Period 2. Participants will receive cenerimod 2 mg for 6 months and end study treatment at the Month 12 visit.

    Drug: cenerimod 2 mg (ex-4 mg)

  • Placebo comparator
    Placebo (Ex-4mg)

    Half the participants that complete treatment with cenerimod 4 mg in Treatment Period 1 will be re-randomized to placebo (matching cenerimod) once daily in addition to background SLE therapy during Treatment Period 2. Participants will receive cenerimod 2 mg for 6 months and end study treatment at the Month 12 visit.

    Drug: Placebo

  • Experimental
    Cenerimod 4 mg

    Participants will received cenerimod 4 mg once daily in addition to background SLE therapy for up to 6 months in Treatment Period 1. The participants randomized to the 4 mg treatment who were still on treatment at Month 6 were re-randomized in a 1:1 ratio to placebo or cenerimod 2 mg to enter Treatment Period 2. The participants who did not complete 6 months of cenerimod 4 mg treatment will be analyzed in the "Non Re-randomized (Ex-4mg)" treatment group.

    Drug: Cenerimod 4 mg

  • Placebo comparator
    Placebo

    Participants will receive placebo (matching cenerimod) once daily in addition to background SLE therapy. Treatment Period 1 is 6 months long. It will start with the administration of the first dose of study treatment, after randomization, and end at the Month 6 visit. All randomized participants need to complete Treatment Period 1 before continuing in Treatment Period 2. In Treatment Period 2 participants will continue with placebo (matching cenerimod) for a further 6 months and end study treatment at the Month 12 visit.

    Drug: Placebo

Interventions

  • Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg

  • Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg

  • Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg

  • Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg

  • DrugPlacebo

    Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod

  • Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Month 6 in the Modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) Score

    The primary endpoint is the absolute change from baseline in the modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) score. The SLEDAI-2K is a cumulative index of lupus disease activity scored by the physician. It is calculated from 24 individual descriptors across 9 organ systems, with weighted scores of 2-8, and measures disease activity within the last 10 days. 0 points indicates inactive disease, and 105 points is the maximum possible score. In this study the SLEDAI-2K was modified, to exclude leucopenia (minus 1 point), due to the mechanism of action of cenerimod. Improvement in systemic lupus erythematosus disease activity is defined as a reduction in SLEDAI-2K score of greater than or equal to 4. A decreased score, i.e., a negative change, indicates an improvement in systemic lupus erythematosus disease activity from baseline to Month 6.

    Time frame: Baseline (Day 1) and Month 6

Secondary outcomes

  1. Response on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Month 6 as Compared to Baseline

    A responder could only be assessed if the full information of all body systems was available. A participant was defined as a responder based on the Systemic Lupus Erythematosus Responder Index 4 (SRI-4) was a composite, binary endpoint based on three variables: * mSLEDAI-2K score had to have a reduction from baseline greater than or equal to 4, * Physician Global Assessment (PGA) had to have an increase from baseline less than or equal to 0.3. The PGA is a 100 mm visual analog scale used by the physician to assess disease activity ranging for 0 to 3. The scale is anchored with values from 0 = "none" and 3 = "severe"), and * BILAG-2004 (no new BILAG A organ domain score and at most one new BILAG B organ domain score) compared with baseline. If one of the SRI-4 mSLEDAI-2K, PGA and BILAG variables were not met the subject was scored a non-responder. Participants that did not fit at least one of the above criteria were assigned to the missing group.

    Time frame: Baseline (Day 1) and Month 6

  2. British Isles Lupus Assessment Group-2004 (BILAG) Disease Activity Index Response at Month 6

    The British Isles Lupus Assessment Group-2004 (BILAG) is a comprehensive tool used by the physician to assess disease activity and is sensitive to small changes over time. Response (no worsening) at Month 6 on BILAG-2004 disease activity index was defined as no new BILAG A organ domain score and no more than one new BILAG B organ domain score compared with baseline. No analysis is reported because the model did not meet the convergence criteria.

    Time frame: Baseline (Day 1) and Month 6

07

Results

Posted Sep 22, 2023

Participant flow

The study was done from 21 December 2018 to 25 August 2022.

Treatment Period 1 (1st dose - Month 6)
Participant flow — Treatment Period 1 (1st dose - Month 6)
MilestoneCenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 2 mg (Ex-4 mg)Placebo (Ex-4 mg)Cenerimod 4 mgPlacebo
Started858586008586
Completed787871007077
Not completed771500159
Withdrew: Death0100000
Withdrew: Adverse event0140032
Withdrew: Withdrawal by subject4120024
Withdrew: Lost to follow-up0100010
Withdrew: Pre-specified criteria1370061
Withdrew: Randomized but no study treatment taken0000010
Withdrew: Other reasons2020021
Withdrew: Lack of efficacy0000001
Treatment Period 2 (Month 6 - Month 12)
Participant flow — Treatment Period 2 (Month 6 - Month 12)
MilestoneCenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 2 mg (Ex-4 mg)Placebo (Ex-4 mg)Cenerimod 4 mgPlacebo
Started7878723535077
Completed7474593035068
Not completed44135009
Withdrew: Adverse event1231004
Withdrew: Withdrawal by subject0022001
Withdrew: Lost to follow-up0120000
Withdrew: Lack of efficacy1000001
Withdrew: Pre-specified criteria0132002
Withdrew: Other reasons2020001
Withdrew: Discontinued study treatment in treatment period 1, re-randomized in error0010000

Outcome measures

PrimaryChange From Baseline to Month 6 in the Modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) Score

The primary endpoint is the absolute change from baseline in the modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) score. The SLEDAI-2K is a cumulative index of lupus disease activity scored by the physician. It is calculated from 24 individual descriptors across 9 organ systems, with weighted scores of 2-8, and measures disease activity within the last 10 days. 0 points indicates inactive disease, and 105 points is the maximum possible score. In this study the SLEDAI-2K was modified, to exclude leucopenia (minus 1 point), due to the mechanism of action of cenerimod. Improvement in systemic lupus erythematosus disease activity is defined as a reduction in SLEDAI-2K score of greater than or equal to 4. A decreased score, i.e., a negative change, indicates an improvement in systemic lupus erythematosus disease activity from baseline to Month 6.

Time frame:
Baseline (Day 1) and Month 6
Reported as:
Least squares mean · score on a scale
Change From Baseline to Month 6 in the Modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) Score
score on a scaleCenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlacebo
Change From Baseline to Month 6 in the Modified Systemic Lupus Erythematosus Activity Index 2000 (mSLEDAI-2K) Score-3.2 (-3.98 to -2.49)-3.41 (-4.16 to -2.67)-2.84 (-3.58 to -2.09)-4.04 (-4.79 to -3.28)-2.85 (-3.60 to -2.10)
Statistical analysis
  • Cenerimod 0.5 mg vs Placebo · Mixed Models Analysis · p = 0.4749 · Ls mean difference to placebo: -0.39 · 95% CI -1.45 to 0.68
  • Cenerimod 1 mg vs Placebo · Mixed Models Analysis · p = 0.2941 · Ls mean to placebo: -0.57 · 95% CI -1.65 to 0.49
  • Cenerimod 2 mg vs Placebo · Mixed Models Analysis · p = 0.9802 · Ls mean difference to placebo: 0.01 · 95% CI -1.05 to 1.08
  • Cenerimod 4 mg vs Placebo · Mixed Models Analysis · p = 0.0291 · Ls mean difference: -1.19 · 95% CI -2.25 to -0.12
SecondaryResponse on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Month 6 as Compared to Baseline

A responder could only be assessed if the full information of all body systems was available. A participant was defined as a responder based on the Systemic Lupus Erythematosus Responder Index 4 (SRI-4) was a composite, binary endpoint based on three variables: * mSLEDAI-2K score had to have a reduction from baseline greater than or equal to 4, * Physician Global Assessment (PGA) had to have an increase from baseline less than or equal to 0.3. The PGA is a 100 mm visual analog scale used by the physician to assess disease activity ranging for 0 to 3. The scale is anchored with values from 0 = "none" and 3 = "severe"), and * BILAG-2004 (no new BILAG A organ domain score and at most one new BILAG B organ domain score) compared with baseline. If one of the SRI-4 mSLEDAI-2K, PGA and BILAG variables were not met the subject was scored a non-responder. Participants that did not fit at least one of the above criteria were assigned to the missing group.

Time frame:
Baseline (Day 1) and Month 6
Reported as:
Number · participants
Response on Systemic Lupus Erythematosus Responder Index 4 (SRI-4) at Month 6 as Compared to Baseline
participantsCenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlacebo
Responder3641384134
Non-responder4538413643
Missing46789
Statistical analysis
  • Cenerimod 0.5 mg vs Placebo · Mixed Models Analysis · p = 0.974 · Odds ratio (or): 1.01 · 95% CI 0.54 to 1.9
  • Cenerimod 1 mg vs Placebo · Mixed Models Analysis · p = 0.2845 · Odds ratio (or): 1.42 · 95% CI 0.75 to 2.65
  • Cenerimod 2 mg vs Placebo · Mixed Models Analysis · p = 0.5115 · Odds ratio (or): 1.23 · 95% CI 0.66 to 2.32
  • Cenerimod 4 mg vs Placebo · Mixed Models Analysis · p = 0.5115 · Odds ratio (or): 1.23 · 95% CI 0.66 to 2.32
SecondaryBritish Isles Lupus Assessment Group-2004 (BILAG) Disease Activity Index Response at Month 6

The British Isles Lupus Assessment Group-2004 (BILAG) is a comprehensive tool used by the physician to assess disease activity and is sensitive to small changes over time. Response (no worsening) at Month 6 on BILAG-2004 disease activity index was defined as no new BILAG A organ domain score and no more than one new BILAG B organ domain score compared with baseline. No analysis is reported because the model did not meet the convergence criteria.

Time frame:
Baseline (Day 1) and Month 6
Reported as:
Number · percentage of participants
British Isles Lupus Assessment Group-2004 (BILAG) Disease Activity Index Response at Month 6
percentage of participantsCenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlacebo
British Isles Lupus Assessment Group-2004 (BILAG) Disease Activity Index Response at Month 698.898.797.598.797.4

Adverse events

Collected over Treatment-emergent Adverse Events (TEAEs) are reported. TEAEs are defined as adverse events with onset on or after the date of first intake of double-blind study treatment up to end of treatment plus 6 months (i.e., maximum of 18 months: Treatment Period 1 + Treatment Period 2 + 6-month safety follow-up period). Subjects who received cenerimod 4 mg and completed Treatment Period 1 were re-randomized to cenerimod 2 mg or placebo in Treatment Period 2.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cenerimod 0.5 mg (Treatment Period 1 & 2)0/84 (0%)4/84 (4.8%)37/84 (44%)
Cenerimod 1 mg (Treatment Period 1 & 2)2/85 (2.4%)12/85 (14.1%)54/85 (63.5%)
Cenerimod 2 mg (Treatment Period 1 & 2)0/87 (0%)4/87 (4.6%)53/87 (60.9%)
Cenerimod 4 mg (Treatment Period 1) & Cenerimod 2 mg (Ex-4 mg; Treatment Period 2)0/35 (0%)1/35 (2.9%)23/35 (65.7%)
Cenerimod 4 mg (Treatment Period 1) & Placebo (Ex-4 mg; Treatment Period 2)0/35 (0%)0/35 (0%)20/35 (57.1%)
Cenerimod 4 mg (Treatment Period 1) & Not Re-randomized (Ex-4 mg; Treatment Period 2)0/14 (0%)2/14 (14.3%)13/14 (92.9%)
Placebo (Treatment Period 1 & 2)0/86 (0%)6/86 (7%)39/86 (45.3%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventCenerimod 0.5 mg (Treatment Period 1 & 2)Cenerimod 1 mg (Treatment Period 1 & 2)Cenerimod 2 mg (Treatment Period 1 & 2)Cenerimod 4 mg (Treatment Period 1) & Cenerimod 2 mg (Ex-4 mg; Treatment Period 2)Cenerimod 4 mg (Treatment Period 1) & Placebo (Ex-4 mg; Treatment Period 2)Cenerimod 4 mg (Treatment Period 1) & Not Re-randomized (Ex-4 mg; Treatment Period 2)Placebo (Treatment Period 1 & 2)
CellulitisInfections and infestations0/840/850/870/350/351/140/86
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/842/850/870/350/351/141/86
Ovarian cystReproductive system and breast disorders0/840/850/870/350/351/140/86
Hypertensive emergencyVascular disorders0/840/850/871/350/350/140/86
Acute coronary syndromeCardiac disorders0/842/850/870/350/350/140/86
COVID-19Infections and infestations0/842/850/870/350/350/140/86
COVID-19 pneumoniaInfections and infestations1/842/850/870/350/350/141/86
Upper gastrointestinal haemorrhageGastrointestinal disorders1/841/850/870/350/350/140/86
PneumoniaInfections and infestations1/841/850/870/350/350/140/86
HypoglycaemiaMetabolism and nutrition disorders1/840/850/870/350/350/140/86
Most frequent other events
Showing 10 of 51
Most frequent other events
EventCenerimod 0.5 mg (Treatment Period 1 & 2)Cenerimod 1 mg (Treatment Period 1 & 2)Cenerimod 2 mg (Treatment Period 1 & 2)Cenerimod 4 mg (Treatment Period 1) & Cenerimod 2 mg (Ex-4 mg; Treatment Period 2)Cenerimod 4 mg (Treatment Period 1) & Placebo (Ex-4 mg; Treatment Period 2)Cenerimod 4 mg (Treatment Period 1) & Not Re-randomized (Ex-4 mg; Treatment Period 2)Placebo (Treatment Period 1 & 2)
LymphopeniaBlood and lymphatic system disorders4/8410/8512/877/354/355/141/86
HeadacheNervous system disorders11/8412/858/878/352/351/144/86
HypertensionVascular disorders2/848/853/878/350/350/142/86
COVID-19Infections and infestations8/848/8510/871/352/352/1411/86
Lymphocyte count decreasedInvestigations0/840/855/870/351/352/140/86
Upper respiratory tract infectionInfections and infestations7/844/855/874/352/351/141/86
Urinary tract infectionInfections and infestations2/842/852/874/350/351/149/86
Dry eyeEye disorders3/842/859/870/352/350/143/86
DiarrhoeaGastrointestinal disorders4/844/853/873/350/350/143/86
NasopharyngitisInfections and infestations5/840/856/873/351/351/145/86

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlaceboTotal
Mean42.8 ± 12.4140.0 ± 12.7742.2 ± 12.0642.1 ± 10.4441.0 ± 11.9441.6 ± 11.94
Age, Customized
Age, Customized(years)Cenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlaceboTotal
Between 18 and 45 years4954495057259
Between 45 and 64 years3129363327156
Between 64 and 75 years5212212
Sex: Female, Male
Sex: Female, Male(Participants)Cenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlaceboTotal
Female7983808282406
Male6263421
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlaceboTotal
Hispanic or Latino161718191989
Not Hispanic or Latino6968686566336
Unknown or Not Reported000112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlaceboTotal
American Indian or Alaska Native5361318
Asian5976633
Native Hawaiian or Other Pacific Islander000011
Black or African American36810633
White7267656568337
More than one race000000
Unknown or Not Reported000325
Region of Enrollment
Region of Enrollment(participants)Cenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlaceboTotal
Bulgaria5213213
Chile1325718
Czechia222017
France000101
Georgia5314215
Greece001001
Israel011002
Italy110114
Mexico106106739
Philippines4765527
Poland6233721
Romania100102
Russia2875224
Spain120047
Taiwan001102
Thailand020002
Turkey001001
Ukraine3629292729150
United Kingdom000213
United States111721211888
Body Mass Index
Body Mass Index(kilograms/square meter)Cenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlaceboTotal
Mean25.67 ± 5.6725.55 ± 5.9526.16 ± 6.626.82 ± 7.1526.49 ± 6.2426.14 ± 6.33
modified SLEDAI at baseline
modified SLEDAI at baseline(units on a scale)Cenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlaceboTotal
Mean9.8 ± 2.6910.1 ± 3.719.5 ± 2.8810.0 ± 2.5010.2 ± 3.059.9 ± 2.99
08

Study locations

148 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • University of California San Diego
    La Jolla, California 92037-0493, United States
  • Valerius Medical Group and Research Center
    Los Alamitos, California 90720-5403, United States
  • University of Colorado School of Medicine
    Aurora, Colorado 80045, United States
  • Robert W Levin MD PA
    Clearwater, Florida 33765, United States
  • Center for Rheumatology Immunology and Arthritis
    Fort Lauderdale, Florida 33309, United States
  • Life Clinical Trials
    Margate, Florida 33063, United States
  • D&H National Research Centers INC
    Miami, Florida 33155, United States
  • San Marcus Research Clinic
    Miami Lakes, Florida 33014, United States
  • Millennium Research
    Ormond Beach, Florida 32174-1139, United States
  • Integral Rheumatology & Immunology Specialists
    Plantation, Florida 33324, United States
  • Advanced Research Institute Inc Allergy & Rheumatology
    St. Petersburg, Florida 33708, United States
  • Axiom Clinical Research of Florida
    Tampa, Florida 33603, United States
  • North Georgia Rheumatology Group - Duluth
    Lawrenceville, Georgia 30046, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Innovative Health Research
    Las Vegas, Nevada 89128, United States
  • New York Presbyterian Columbia University Medical Center
    New York, New York 10032, United States
  • State University of New York Upstate Medical University
    Syracuse, New York 13210, United States
  • Joint Muscle Medical Care and Research Institute - Lilington Office
    Charlotte, North Carolina 28204, United States
  • DJL Clinical Research
    Charlotte, North Carolina 28210, United States
  • Paramount Medical Research and Consulting
    Middleburg Heights, Ohio 44130, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Office of Ramesh C. Gupta, MD
    Memphis, Tennessee 38119, United States
  • Amarillo Center for Clinical Research
    Amarillo, Texas 79124, United States
  • Accurate Clinical Research
    Houston, Texas 77034, United States
  • Southwest Rheumatology Research, LLC
    Mesquite, Texas 75150, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Accurate Clinical Management
    Stafford, Texas 77477, United States
  • Multiprofile Hospital For Active Treatment Trimontium
    Plovdiv, Plodiv 4002, Bulgaria
  • University Multiprofile Hospital for Active Treatment Pulmed
    Plovdiv, 4002, Bulgaria
  • Diagnostic and Consulting Center "Aleksandrovska" EOOD
    Sofia, 1431, Bulgaria
  • Diagnostic Consulting Center Fokus-5
    Sofia, 1463, Bulgaria
  • Enroll SpA
    Santiago, 7500588, Chile
  • Biomedica Research Group
    Santiago, 7500710, Chile
  • Meditek Ltda.
    Santiago, 8330008, Chile
  • Prosalud
    Santiago, 8380456, Chile
  • Clinical Research Chile SpA
    Valdivia, 5110683, Chile
  • CCR Pardubice
    Pardubice, Vychodocesky KRAJ 530 02, Czechia
  • Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest
    Brest, Brittany Region 29609, France
  • Hôpital Haut-Lévêque
    Pessac, 33604, France
  • LTD "New Plasma Clinic"
    Batumi, 6010, Georgia
  • Aversi Clinic LTD
    Tbilisi, 0160, Georgia
  • Medi Club Georgia Ltd.
    Tbilisi, 0160, Georgia
  • Ltd. Mtskheta Street Clinic
    Tbilisi, 0179, Georgia
  • The First Medical Center Ltd.
    Tbilisi, 0180, Georgia
  • LLC "Innova"
    Tbilisi, 0186, Georgia
  • LLC Raymann
    Tbilisi, 0186, Georgia
  • LTD "Tbilisi Heart Center"
    Tbilisi, 0186, Georgia
  • Medicore
    Tbilisi, 0186, Georgia
  • Multiprofile Clinic Consilium Medulla
    Tbilisi, 0186, Georgia
  • Städtisches Klinikum Karlsruhe gGmbH
    Karlsruhe, 76133, Germany
  • General Hospital of Athens "Laiko"
    Goudi, 11527, Greece
  • Egyesitett Szent Istvan es Szent Laszlo Korhaz Rendelointezet
    Budapest, Budapest 1097, Hungary
  • Rambam Healthcare Campus
    Haifa, 3109601, Israel
  • Bnai Zion Medical Center
    Haifa, 3339419, Israel
  • Galilee Medical Center
    Nahariya, 2210001, Israel
  • The Chaim Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • A.O. Mauriziano Umberto I di Torino
    Torino, Torino 10128, Italy
  • LUPUS CLINIC c/o DIMI
    Genova, 16132, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Roma, 00158, Italy
  • Fondazione Policlinico Universitario A. Gemelli
    Roma, 00168, Italy
  • Tomakomai City Hospital
    Tomakomai-shi, 053-0034, Japan
  • Consultorio Particular Dr. Miguel Cortés Hernández
    Cuernavaca, 62448, Mexico
  • Centro Integral en Reumatología S.A. de C.V.
    Guadalajara, 44160, Mexico
  • Icle S.C.
    Guadalajara, 44600, Mexico
  • Consultorio Privado de Especialidad del Dr. José Javier Orozco Alcalá
    Guadalajara, 44650, Mexico
  • Consultorio Médico del Dr. Federico Galván Villegas
    Guadalajara, 45040, Mexico
  • Morales Vargas Centro de Investigación S.C.
    León, 37000, Mexico
  • Karla Adriana Espinosa Bautista
    Mexico City, 01120, Mexico
  • Centro de Investigación Clínica GRAMEL, S.C.
    Mexico City, 03720, Mexico
  • Biológicos Especializados S.A. de C.V.
    Mexico City, 6700, Mexico
  • Unidad de Atención Médica e Investigación en Salud
    Mérida, 97000, Mexico
  • Kohler & Milstein Research S.A. de C.V.
    Mérida, 97070, Mexico
  • Accelerium, S. de R.L. de C.V.
    Monterrey, 64000, Mexico
  • UBAM Unidad Biomédica Avanzada Monterrey
    Monterrey, 64460, Mexico
  • SMIQ, S. de R.L. de C.V.
    Querétaro, 76070, Mexico
  • Hospital Universitario "Dr. Gonzalo Valdés Valdés"
    Saltillo, 25000, Mexico
  • Unidad de Investigaciones Reumatológicas A.C.
    San Luis Potosí City, 78290, Mexico
  • Centro de Atención e Investigación Cardiovascular del Potosí, S.C.
    San Luis Potosí City, Mexico
  • Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.
    Zapopan, 45030, Mexico
  • Lipa Medix Medical Center
    Lipa City, Batangas 4217, Philippines
  • Angeles University Foundation Medical Center
    Angeles City, Philippines
  • Davao Doctors Hospital
    Davao City, 8000, Philippines
  • Iloilo Doctors Hospital
    Iloilo City, 5000, Philippines
  • Makati Medical Center
    Makati City, 1229, Philippines
  • University of the Philippines Manila - Philippine General Hospital
    Manila, 1000, Philippines
  • Jose R. Reyes Memorial Medical Center
    Manila, 1003, Philippines
  • University of Santo Tomas Hospital
    Manila, 1015, Philippines
  • St. Luke's Medical Center
    Quezon City, 1102, Philippines
  • Far Eastern University - Nicanor Reyes Medical Foundation
    Quezon City, 1118, Philippines
  • Szpital Uniwersytecki Number 2 im. dr. Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Intermedius Uslugi Medyczne
    Kościan, 64-000, Poland
  • Szpital Specjalistyczny im. J. Dietla w Krakowie
    Krakow, 30-121, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-363, Poland
  • Twoja Przychodnia Poznańskie Centrum Medyczne
    Poznan, 61-293, Poland
  • Śląskie Centrum Reumatologii, Rehabilitacji i Zapobiegania Niepełnosprawności im gen. Jerzego Zi
    Ustroń, 43-450, Poland
  • Centro Reumatologico de Caguas
    Caguas, 00725, Puerto Rico

Showing the first 100 of 148 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Suffiotti M, Brazauskas P, Keller MP, Berkani O, Seifer G, Cornelisse P, Murphy MJ, Strasser DS. Pharmacodynamics of the S1P1 receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE. Ann Rheum Dis. 2025 Feb;84(2):284-293. doi: 10.1136/ard-2024-226547. Epub 2025 Jan 16. PubMed 39919901 ↗
  • Askanase AD, D'Cruz D, Kalunian K, Merrill JT, Navarra SV, Cahuzac C, Cornelisse P, Murphy MJ, Strasser DS, Trokan L, Berkani O. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2025 Jan;7(1):e21-e32. doi: 10.1016/S2665-9913(24)00246-7. Epub 2024 Nov 22. PubMed 39586304 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Aug 2021, 32 months.

Results were first posted in Sep 2023, 2 years after primary completion. A results delay was requested in Jul 2022.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 47. This study's 32 months is close to that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2018
First posted
Nov 15, 2018
StartActual
Dec 21, 2018
Primary completionActual
Aug 31, 2021
CompletionActual
Aug 25, 2022
Results delay requested
Jul 22, 2022
Results first posted
Sep 22, 2023
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03742037
Responsible party
Sponsor
First posted
Nov 15, 2018
Start date
Dec 21, 2018
Primary completion
Aug 31, 2021
Completion
Aug 25, 2022
Results posted
Sep 22, 2023
Last update
Jul 29, 2026

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenerimod

Start the discussion